One of the most significant but least talked-about developments in American life over the past decade has been our shifting relationship with the stock market. In the past 10 years, as the market has … [Read more...] about The 2010s Changed Investing Forever – And We Need to Stop It
In a Tough Environment for Biotechs, Can the Science at Scynexis Win?
Scynexis (NASDAQ: SCYX) is a clinical stage biotech company based out of New Jersey. The company has one significant drug under development in multiple indications, ibrexafungerp, for the treatment of … [Read more...] about In a Tough Environment for Biotechs, Can the Science at Scynexis Win?
Puma: Surviving, Not Thriving
Puma Biotechnology (NASDAQ: PBYI) is a commercial stage company with an approved oncology drug called Nerlynx, for the treatment of HER2+ breast cancer. The drug was first approved in July 2017, and … [Read more...] about Puma: Surviving, Not Thriving
Amarin Corporation – A Whale of a Story
Amarin (Nasdaq: AMRN) made perhaps the biggest splash in the small-cap biopharmaceutical space last year by announcing trial results from its long-running REDUCE-IT study. The company has a market cap … [Read more...] about Amarin Corporation – A Whale of a Story
Geron: The Neverending Story
Geron Corporation (Nasdaq: GERN) is a clinical stage pharmaceutical company with a current market cap of just over $300 million. Geron has one drug in its pipeline, a telomerase inhibitor called … [Read more...] about Geron: The Neverending Story
Verastem Oncology: Looking for a Port in the Storm
Last fall, Verastem Oncology (NASDAQ: VSTM) received FDA-approval for its first drug, Copiktra, an oral monotherapy for the treatment of relapsed or refractory chronic lymphotic leukemia, small … [Read more...] about Verastem Oncology: Looking for a Port in the Storm
You must be logged in to post a comment.